Abbvie Inc.

Zhihong Liu

Chung-Ming Hsieh

Lorenzo Benatuil

Yuliya Kutskova

Jijie Gu

Jonathan A Hickson

Susan Elizabeth Morgan-Lappe

Erwin R Boghaert

Yingchun Li

Maria Harris

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Therapeutic DLL4 binding proteins

Growing community of inventors

Gurnee, IL, United States of America

Zhihong Liu